Optimus Diagnostics
Explainable interpretationat the point of care.
A concept-learning engine designed to read what a camera, probe or scanner already sees, at the bedside, in the operating room and through recovery, and to state the reasoning behind every output.
Development stage. Optimus Diagnostics is a pre-revenue company. No Optimus product is cleared or authorized by the FDA or any other regulator, and nothing described on this site is available for clinical sale or for diagnostic use. Product descriptions are statements of intended development, not of present capability.
The gap
Seeing without sight
Care has moved out of the hospital and into the home and the clinic. The contact is there, the camera is there and the clinician is there. The interpretation is not, and that is the gap this company exists to close.
What the point of care already has
The hardest asset to build
- Consented contact with the patient before, during and after a procedure
- Imaging already captured, including the preoperative CT the case requires
- Licensed surgeons and clinicians with a standing reason to act
- A planning and procedure record of exactly what was done
- Hospital and payor reimbursement written on procedure and outcome
What is missing
The interpretation layer
- Seeing the rare anatomy that changes the surgical plan
- Reading the echo that clears an older patient for surgery
- Catching a wound breakdown at stage one rather than stage three
- Reading the skin of a patient on chronic immunosuppression
- Recognizing the drug eruption that says a regimen is causing harm
The engine
Explainable by design
Optimus licenses a concept-learning engine that is not a neural network. It learns a clinical concept from a small number of real examples and states the properties behind every output. Four characteristics matter in medicine, and conventional deep learning struggles to deliver them at the same time.
Few-shot
Learns a concept from a handful of real examples rather than millions of labeled images.
Explainable
Names the properties behind each output, so a clinician reviews the basis rather than a score.
Edge-native
Designed to run on a single low-power processor. No cloud round trip, and no image need leave the device.
Robust
Built for poor lighting, occlusion, motion and the uncommon presentations that thin out training sets.
Where conventional models run out of data
A trained model needs volume, so it performs on common presentations in well-photographed populations and degrades on rare disease, on darker skin tones, on paediatric anatomy and on the long tail of generic drug appearances. Those are the cases where the clinical need is greatest.
Why the reasoning matters more than the score
A surgeon, a payor and a regulator each have to stand behind a decision. An output that cannot say why it was produced is difficult to review, to adjudicate and to submit, whatever its accuracy. Stated reasoning is a condition of operating here, not a feature.
The underlying engine is licensed from a third-party licensor and is not owned by Optimus Diagnostics. Characteristics described above reflect the licensor's technology as applied to the fields Optimus licenses.
The architecture
No data centers. No GPUs.
Conventional medical artificial intelligence is a deep neural network. It performs billions of matrix operations, which standard processors cannot do quickly, so it needs graphics hardware or a cloud cluster. A concept-learning engine is not a neural network, and that single difference is what allows it to run inside the device.
Conventional deep learning stack
The licensed engine
Concepts, boundaries and rules with graded confidence values, in place of billions of statistical weights.
No connection required
A portable probe or field monitor can work in a rural clinic or a basement with no signal.
No data leaves
Patient information can stay on the device, which removes a class of breach exposure and simplifies compliance.
No round trip
Results land locally rather than waiting on a server across the country.
No new hardware
Designed for the standard processors manufacturers already ship, with no graphics hardware to buy or power.
The platform
The clinical cores
The expensive work is the perception core: the image pipeline, the concept library, the explainability layer and the clinical data infrastructure. Built and validated once, it is then pointed at separate clinical questions, each of which carries its own validation and its own regulatory route.
DermScope
Skin surface perception, validated once and pointed at four clinical questions. Wounds, lesions and drug reactions are read at the point of contact, and the same core reads the same skin again over time.
- Wound pressure injury, ulcer and surgical incision
- Detect skin cancer triage
- Safety cutaneous adverse drug reactions
- Monitor longitudinal change over time
CardioScope
Cardiac image and rhythm interpretation at the point of care, read on the probe itself. Labeled examples are scarcest here, which is where learning a clinical concept from a handful of verified cases is worth the most.
- Echo function estimates from a handheld probe
- Rhythm atrial fibrillation and conduction
- Flow valve assessment on Doppler
SpineScope
Spinal planning, guidance and follow-up on one perception core, deployed inside a personalized planning workflow that builds every implant from the patient's own CT. Rare anatomy is enrolled from a handful of verified cases, every measurement carries the geometry behind it, and a surgeon approves each plan.
- Plan rare-anatomy segmentation from the preoperative CT
- Guide intraoperative read against the approved plan
- Track fusion and alignment on follow-up films
Product names and applications describe development intent. No product listed above is cleared or authorized for clinical use, and each is subject to regulatory review before any commercial availability. Sequencing and timing are estimates and are not commitments.
Deployment
Software that arrives with its distribution
The engine is designed to run on assets a partner has already built and paid for. That is the difference between clinical software that has to buy its way to the patient and software that arrives inside a channel which already reaches them.
| What the partner already has | What it makes possible | Why it is hard to assemble later |
|---|---|---|
| A planning workflow that reads every preoperative CT | SpineScope Plan on every case | Every case already passes through it |
| Follow-up radiographs on every patient | Fusion and alignment read over time | Longitudinal imaging needs access that builds over years |
| Licensed clinicians inside the workflow | All three cores | Every output needs a human with the authority to act |
| A specialty or complex-therapy population | Cutaneous surveillance on a high-risk cohort | Assembled patient by patient over years |
| Recurring, consented in-home visit cadence | Longitudinal change tracking | Longitudinal imaging needs physical access over time |
| An existing quality and regulatory system | Every submission in the plan | Quality and post-market surveillance already stood up |
One new element
The engine is inserted into a sequence that already runs, and changes nothing on either side of it.
No new data collection
The comparison uses the dispensed record the partner already holds. Nothing new is collected from the patient.
No new workflow
A flagged level enters the review queue that exists today, in the same shape as every other exception a planning engineer works.
Market
An overlay on installed hardware
Optimus licenses software that runs on the cameras, probes, workstations and imaging systems a partner has already bought and installed, so the market it reaches is measured in installed base rather than in units shipped.
Total addressable market
Global point-of-care diagnostics, medical imaging and surgical planning software, remote monitoring and digital health software.
SpineScope
Personalized spinal planning, intraoperative guidance against the approved plan, and fusion and alignment assessment on the follow-up films every spine patient already receives.
Unit of accountPlanned cases
DermScope
Wound and skin integrity assessment, skin cancer triage, cutaneous drug safety surveillance and longitudinal monitoring, read at the point of contact rather than in a specialist clinic.
Unit of accountClinician seats
CardioScope
Point-of-care echocardiography, ejection fraction estimation and valvular flow evaluation at the bedside rather than in the reading room.
Unit of accountClinician seats
The market figure above is an internal estimate assembled from published industry sizing for point-of-care diagnostics, medical imaging software, remote monitoring and digital health software. It describes the scope of the markets these cores address. It is not a forecast of Optimus Diagnostics revenue, and no product described on this site is cleared or authorized for clinical use.
Research and OEM
Where the core gets embedded
The perception core is built to be licensed into instruments and studies that someone else owns and already runs. Three groups are a direct fit.
Academic medical centers
Few-shot learning suits a cohort that is rigorously characterized rather than merely large, which is what an investigator-led dataset usually is.
- Retrospective work on an existing image library
- A sub-study inside a protocol already running
- Reader studies run against the concept trace, not a score alone
Contract research organizations
An explainable read that behaves the same way at every site keeps endpoint assessment from drifting between readers and locations.
- Consistent capture on trial-supplied hardware
- Per-case reasoning retained for audit
- Runs at the site on one CPU, with no network dependency
Device manufacturers
Interpretation added to an instrument already built, without adding silicon to the bill of materials or a cloud round trip to the workflow.
- Runs on the compute already inside the device
- No GPU and no data center dependency
- Integrated as a component under the partner's quality system
What Optimus brings
- The trained perception core, tuned to the partner's capture conditions
- The concept trace behind every output, in a form a reviewer can follow
- Integration support and documentation written for the partner's quality system
What the partner brings
- The instrument, the image library or the study population the work runs on
- The clinical question that is worth answering at the point of care, and the reason it is worth answering there
- Licensed clinicians inside the workflow, and the regulatory pathway they already hold
Clinical foundation
Built with the clinicians who use it
The engine's founding medical application was developed in wound healing research, and each product is designed around a step a clinician already takes. That is the difference between a tool that is adopted and one that is bypassed.
Board member and clinical advisor
John W. Harmon, MD
Wound healing and surgical research, Johns Hopkins Medicine. The engine's founding medical application was developed with him, and he is the clinical anchor for the DermScope validation program.
Board member and clinical advisor
S. M. Hosseini, MD
Clinical workflow design, Johns Hopkins Medicine. Each product is built around a step a clinician already takes, rather than adding one.
Validation before contract
Concordance work is designed to run inside a partner's own operation, against a verification step the partner already performs.
Hard cases named in advance
Reformulated generics, split tablets, worn imprints and look-alike pairs are specified before a study opens rather than excluded afterwards.
Silence is the default
A reading that reconciles writes a record, not an alert. Alert fatigue is the common failure mode in this category.
Institutional affiliations are shown to identify an individual's professional role. They do not indicate review, sponsorship or endorsement of Optimus Diagnostics by Johns Hopkins Medicine or any other institution.
Regulatory position
Where the line sits
We would rather state this plainly than have a partner discover it in diligence. The first deployment reaches use as validated design software inside a partner's quality system, and every product beyond it carries its own submission.
On this side of the line
A design aid inside a reviewed planning workflow. The engine proposes segmentation and measurements to a planning engineer working inside the partner's quality system, and the surgeon approves every plan before anything is manufactured. Both review the properties behind each output rather than rely on it.
What would cross it
Autonomy, or a clinical claim. The position changes when an output drives the plan with no engineer review, when the software reads images in the operating room, or when it makes a diagnostic claim on follow-up films. Each of those is a regulated device function and carries its own submission.
Statement of status
Optimus Diagnostics holds no FDA clearance, authorization or approval. No product described on this site is currently available for sale, for clinical use or for diagnostic use in the United States or in any other jurisdiction.
Descriptions of DermScope and CardioScope, and of SpineScope applications beyond the design aid configuration, describe intended development. Each requires a regulatory submission and a determination by the relevant authority before it may be marketed. Indicative sequencing reflects management's current expectations and may change.
Nothing on this site is medical advice, and nothing here is intended to support a clinical decision. Patients should speak with a qualified clinician.
The company
Who is building this
Optimus Diagnostics licenses a horizontal perception platform into defined medical fields of use and builds the clinical, regulatory and commercial layer around it.
Co-Founder and Board Member
Dr. Rob Sobhani
Business growth, partnerships and route to market. Founder and chief executive of Sparo, and thirty-five years advising chief executives and governments on regulated enterprises. Ph.D., Georgetown University.
Co-Founder and Chairman of the Board
Gary LaDrido
Corporate development and capital formation. Founder of Kingmaker Inc., the AI lab and AI venture studio in which Optimus was formed, and of Redrock Ventures, a late-stage frontier technology investor. More than twenty-five years in global capital markets, with over $15 billion in transactions.
Chief Financial Officer
Ian Gerrard
Finance, capital raising and transactions. Forty years as a finance executive, including Chief Financial Officer of COMSAT International, which he carried through a turnaround and its sale to British Telecom. Earlier an Executive Director at Global One. MBA, American University.
Contact
Partner and platform inquiries
We are speaking with surgical planning platforms, medical imaging and device manufacturers, health systems and point-of-care hardware companies whose installed base already reaches the patient.
What is useful in a first conversation
- The population your platform already reaches, and how contact recurs
- The hardware already placed with that population
- Whether licensed clinicians sit inside your workflow today
- The quality and regulatory system already in place
The more of this the form carries, the shorter the first call needs to be.